SmartStream and Credit Suisse Expand their Agreement from the Processing of Invoices and Reconciliations to Now Include Listed Derivatives Brokerage Fees
SmartStream Technologies, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announced that its original agreement with Credit Suisse was recently expanded to include the processing of Listed Derivatives Brokerage fees which began in February of this year. This expansion in SmartStream’s partnership with Credit Suisse complements its existing managed service solution for the processing of invoices and reconciliations within Credit Suisse’s OTC Fixed Income Derivatives, US Listed Equity Options and Cash Equities businesses across brokerage, clearing and exchange fees operations, which began in June of 2016. The managed service enables the bank to advance the operational efficiencies created through the use of the utility-based solutions offered by SmartStream, utilizing their proprietary execution fees and expense management software.
By centralizing the entire cost management ecosystem across all service providers from receipt of invoice to automatic fee calculation, accruals, reconciliation and payment, the bank can better realize enhanced controls and transparency and achieve greater cost optimization.
Haytham Kaddoura, CEO, SmartStream commented, "We are very excited about the opportunity to further support Credit Suisse in its strategic endeavors. Our fees and invoice management solutions have proven time and again their ability to deliver key cost and operational efficiencies at tier one financial institutions around the world."
Note to Editors
About SmartStream Technologies
SmartStream provides Transaction Lifecycle Management (TLM®) solutions and Managed Services to dramatically transform the middle and back-office operations of financial institutions. Over 1,500 clients, including more than 70 of the World's top 100 banks, 8 of the top 10 asset managers, and 8 of the top 10 custodians rely on SmartStream’s solutions.
SmartStream delivers greater efficiency, automation and control to critical post trade operations including: Reference Data Operations, Trade Process Management, Confirmations and Reconciliation Management, Corporate Actions Processing, Fees and Invoice Management, Collateral Management, Cash & Liquidity Management and Compliance Solutions. Used independently or as a suite of solutions and services, clients gain a lower cost-per-transaction whilst reducing operational risk, aiding compliance and improving customer service levels.
For more information about SmartStream visit: www.smartstream-stp.com
For further information
Mark Roth, Chief Marketing Officer, SmartStream Technologies, Inc.
Tel: (212) 763-6509
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Login VSI Announces Free Meltdown/Spectre Emergency Edition17.1.2018 11:00 | Tiedote
Today software solution provider Login VSI (www.loginvsi.com), the industry leader in VDI and DaaS performance testing, announces the temporary availability of a free, full-production, license of their flagship product Login VSI to every organization using Citrix XenApp, Citrix XenDesktop, VMware Horizon, or Microsoft Remote Desktop Services (RDS). This Emergency Edition will be free for all end-user organizations looking to test the performance impact of Meltdown and Spectre security patches, and will be valid until March 31, 2018. This license offers unlimited users, unlimited locations and includes all standard workloads. This special license can be requested through the Login VSI website, and through selected partners in Login VSI’s extensive eco-system of (VDI-performance supporting) software, hardware and service vendors. Login VSI also started a series of lab tests to quantify the exact performance impact of the Meltdown and Spectre patches rolled out today, and will keep doing
Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer17.1.2018 11:00 | Tiedote
Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, today announced that it has expanded its CE mark of the QuantideX® qPCR BCR-ABL IS Kit and QuantideX® qPCR BCR-ABL minor Kit to include clinical use on the Roche Diagnostics cobas z 480 Analyzer. The exquisite sensitivity and precision of the assays support clinicians in the rapidly evolving European clinical practice of therapy cessation for long-term responders on tyrosine kinase inhibitor (TKI) therapies. The available platforms, which also include the Applied Biosystems® 7500 Fast Dx Real-Time PCR instrument, improve the reach of the portfolio in Europe and Latin America. “As a global solutions provider, we are committed to ensuring that our best-in-class CML monitoring assays are widely available to deliver powerful answers that can impact patient decisions,” said Matthew McManus, M.D., Ph.
NTT Com Granted Microsoft's Gold Cloud Platform Status Globally17.1.2018 09:00 | Tiedote
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), is pleased to announce that it has been granted Microsoft Gold Cloud Platform status, the highest accreditation currently available, for its competency in delivering on quality, expertise and differentiated managed services in the cloud. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005911/en/ “Gold status is an important recognition of our competency in the cloud arena,” said Damian Skendrovic, CEO, NTT Com Managed Services. “With Microsoft Cloud Platform Competency we are helping enterprises to manage their hybrid cloud infrastructures, delivering on SaaS and PaaS solutions available in the Azure and Azure Stack marketplace that will enable our customers to optimize on performance and reach their business goals,” As part of its global strategy, NTT Com has been part of the early ado
Premas, IncellDx Ink India Distribution Agreement17.1.2018 08:01 | Tiedote
Premas Life Sciences Pvt., Ltd. and IncellDx, Inc. announced today they have signed an exclusive distribution agreement. The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumors carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry. Included in the deal are: IncellDx's patented single-cell assays for quantifying PD-L1 on tumor cells and immune cell subtypes; patented single-cell assay for HPV E6, E7 mRNA detection in cervical samples; and, its incellPREP single-cell preparation kit for solid tissues including tumors. Researchers at AIIMS, New Delhi have completed a successful study utilizing IncellDx's next generation (3Dx) investigational molecular assay which quantifies E6, E7 mRNA overexpression in single cells simultaneously with the measurement of cell cycle and cell proliferation, the hallmark of progressive disease. Praveen Gupta, Managing Director of Premas Life Sciences commented: “India’s molecular
Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma17.1.2018 01:05 | Tiedote
Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) and Exelixis, Inc. (NASDAQ:EXEL) today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC), which will be presented in a late-breaking oral session at the 2018 ASCO-GI Symposium being held in San Francisco, January 18-20, 2018. In CELESTIAL, cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS), the trial’s primary endpoint, at the planned second interim analysis (prespecified critical p value ≤ 0.021) for the population of second- and third-line patients enrolled in this study. Median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76, 95 percent CI 0.63-0.92; p=0.0049). Median progression-free survival (PFS) was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44, 95 percent CI 0.36-0.52; p<0.0001). Objective resp
IFF to Release Fourth Quarter & Full Year 2017 Results February 1417.1.2018 00:15 | Tiedote
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced that it will release its fourth quarter and full year 2017 earnings results following the market close on Wednesday, February 14, 2018. The management team will host a live webcast on Thursday, February 15, 2018 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumer
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme